Mirion's Nuclear Momentum Is Real, but a China Debook and Medical Softness Cloud the Tape

Backlog up 40%, AI products launch, yet the stock sits 27% off its high — a story of strong orders vs. a skeptical tape

MIR · Earnings Call · 2026-07-29

The Nuclear Wave Continues, But Investors Are Fixated on a China Cancellation

Mirion's second-quarter report is a study in contrast. The company's cancellation of a Chinese new-build order — booked back in 2019 and stalled by geopolitics — dominated the narrative, even as management framed it as immaterial. CEO Thomas Logan called it "disappointing" but emphasized the backlog's quality: "we do not see any level of elevated risk, we do not see this as being some kind of trigger event." Yet the tape disagrees: the stock has fallen 23% over the past 90 days, and the full trend shows a -50% drawdown from the October 2025 peak. This tension between strong operational momentum and a weak price is precisely what makes this quarter interesting. Backlog grew nearly 40% year-over-year to over $1.1 billion, with legacy backlog (excluding Paragon and Certrec) up 17%. Nuclear power orders, ex-M&A, jumped 50%, driven by both the operating fleet and SMRs. The company’s Nuclear power order strength is unambiguous. As CFO Brian Schopfer noted, "we are sitting at a coverage base at the midpoint of our guide is the same as where we sat every year basically for the last couple years." That visibility underpins a maintained full-year guidance, with organic revenue growth expected to accelerate from 2% in H1 to 7.5%–11.2% in H2. Yet the market is not rewarding this. Perhaps the China debook, while small ($18M), raises questions about the stability of legacy international contracts. Or perhaps the medical segment, which saw revenue decline 1% organically, is the bigger worry.

This was a contract that essentially was undergirded by a project that was making very little progress... it has candidly been impacted by some of the changed trading dynamics specifically between the U.S. and China.
Thomas D. Logan, Founder, Chairman, and CEO · 2026-07-29

Medical: The Weak Link

Medical revenue fell 1% organically, below the low-single-digit growth expected in April. The culprits: delayed hardware demand in nuclear medicine and a tough comp in dosimetry. Brian Schopfer explained, "we have just seen a bit of a pause in the first half... we are waiting to see some more momentum in the drug pipeline." He remains optimistic about a second-half pickup, citing strong order growth in the nuclear medicine software business. But the guidance revisions tell a different story: RTQA was raised to double-digit growth, while nuclear medicine was cut to mid-single digits and dosimetry is now expected to be negative for the year. These puts and takes offset, keeping the segment guidance intact, but the market is likely skeptical of the hardware recovery. This is not a new theme. In the Q1 call, management had already flagged medical headwinds, but the persistence is notable. The company's medical segment has been a drag for several quarters, and the current quarter's miss on organic growth is a negative signal.

AI as a Margin Accelerant

One genuinely new development is the depth of AI talk. Thomas Logan outlined a three-pillar AI strategy: product development, organization-wide efficiencies, and AI-powered solutions. He highlighted two new products introduced at the AAPM meeting: AI strategy — specifically the New build in dosimetry, the PlanAI platform, and the Daily QA4 Pro. The company is investing about $5 million in AI spend, which is margin dilutive in the near term but expected to accelerate productivity. In a prior call (Q4 2025), Logan had discussed hiring a Chief AI & Digital officer, and the current call shows that investment translating into product launches. This feels like a step change for Mirion, which historically was seen as a hardware and services company. The AI narrative could eventually support a re-rating, but for now it is too early to tell. The company’s revenue growth in the quarter was 20% (18% from Paragon), with organic at 1% — highlighting the reliance on M&A for top-line expansion. “The third pillar, the one I am most excited about, is AI-powered solutions. We are developing new AI-centric innovations across both segments.” — Thomas D. Logan, Founder, Chairman, and CEO · 2026-07-29 “Our view is that the growth dynamic... is continuing to build. So we are increasingly bullish on this sector.” — Thomas D. Logan, Founder, Chairman, and CEO · 2026-07-29 “We still largely have about 12 opportunities in queue. Eight are we would classify in the new build, so that is both utility scale and SMRs.” — Brian Schopfer, CFO and Medical Group President · 2026-07-29 From the prior call (April 2026), Logan had already been bullish on nuclear: “The biggest single impact is that even though we are seeing life extensions in the American market from 60 years of permitted operating life to 80 years, the majority of operators are really thinking 100.” — Tom Logan, Founder, Chairman and CEO · 2026-04-29 And in the Q1 call, he emphasized the “single most important” driver being the installed base.

Verdict

The Chinese cancellation, though small, is a reminder that legacy contracts carry geopolitical risk. But the company’s core thesis — the installed base is reinvesting at a generational pace — is supported by 50% order growth in nuclear power and a near-40% jump in legacy installed-base backlog. The stock’s drawdown may be overdone, especially given H2 guidance and the new AI-driven products. However, medical remains a question mark. The tape history shows no sector-wide nuclear advance; Mirion is a lone name moving against the broader market's AI/semiconductor focus. This could be an opportunity for patient investors. Operating income turned to -$5M in the latest quarter, yet adjusted EBITDA margins expanded 150bps in Q2. The gap between GAAP losses and adjusted profitability is widening due to M&A charges and one-time items.